Hematology Frontier

In the golden autumn season, experts and scholars gathered in Zhuhai. The 2026 Cross-Strait Hematology Academic Conference was held in Zhuhai, Guangdong, from August 21–22. Hematology experts from both sides of the Taiwan Strait, as well as Hong Kong and Macao, came together to discuss cutting-edge developments, clinical practice, and innovations in nursing. During the conference, Oncology Frontier – Hematology Frontier interviewed Professor Ma Jun of the Harbin Institute of Hematology and Oncology, who shared his perspectives on the rapidly developing field of cell and gene therapy (CGT). He reviewed the global and domestic landscape of approved cell therapy products, real-world clinical data, and China's strengths in innovation, while also discussing challenges related to original research and development, standardization, treatment accessibility, and the future of CGT.

Differential diagnosis of chronic lymphoproliferative disorders (CLPD) remains a major challenge in hematology. Given the blurred boundary between reactive lymphoid proliferation and clonal proliferation, as well as the substantial overlap in morphological and immunophenotypic features among different subtypes, avoiding misdiagnosis and missed diagnosis is of critical importance. During the 2026 Cross-Strait Hematology Academic Conference, Oncology Frontier – Hematology Frontier invited Professor Wei Xu of the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) to systematically explain the diagnostic approach integrating basic morphology, flow cytometric immunophenotyping, and molecular genetic testing. Professor Xu also provided an in-depth analysis of strategies for resolving challenging CLPD cases, offering authoritative guidance for clinicians to establish a standardized, multidimensional, and precise classification system for these disorders.

Editor's Note: In the golden autumn season, colleagues from across the mountains and seas gathered together. The 2026 Cross-Strait Hematology Academic Conference was held in Zhuhai, Guangdong, from August 21…

Medical progress is driven not only by clinical practice and scientific innovation, but also by cross-regional exchange, mutual learning, and the transmission of knowledge and experience. Looking back at the history of hematology collaboration among the Chinese mainland, Taiwan, Hong Kong, and Macao—from the “seeds of life” transported across the Taiwan Strait to continuous breakthroughs in transplantation technology, and from exchanges among young physicians to deepening medical collaboration—each interaction has contributed to advances in diagnosis and treatment and enabled more patients to benefit from improved care.

In the golden autumn season, the Greater Bay Area comes alive, as colleagues from across the mountains and seas come together. The 2026 Cross-Strait Hematology Conference was held with great success in Zhuhai, Guangdong, from August 21–22. Hematology experts and scholars from mainland China, Taiwan, Hong Kong, and Macao gathered to engage in in-depth discussions on topics including cutting-edge developments in the field, clinical practice, and nursing innovation. During the conference, Professor Hou Hsin-An, Conference Chair and President of the Taiwan Society of Hematology, spoke with the media. Drawing on the strong foundation and broad prospects for hematology exchange across the Taiwan Strait, Professor Hou shared forward-looking perspectives on key topics including deepening academic exchange and collaborative cooperation, advancing precision diagnosis and treatment of hematologic diseases, and promoting the development and growth of young hematology professionals.

Bringing together outstanding experts from across the Yanzhao region and remaining committed to its founding mission for fourteen years. On August 21, 2026,the 14th Lu Daopei Hematology Forum officially opened at Hebei Yanda Ludaopei Hospital. Building on fourteen years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. It brought together leading experts and scholars in hematology from across China to explore advances in the field, serving as an important academic platform for promoting progress in the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Dr. Chen Man of Ludaopei Hospital for an exclusive interview. She shared her professional insights on the clinical value of lymphocyte subset monitoring, its application in differentiating complications following hematopoietic stem cell transplantation (HSCT), and future directions in immune monitoring.

Bringing together leading experts and remaining committed to advancing the field, the 14th Lu Daopei Hematology Forum opened on August 21, 2026, at Hebei Yanda Ludaopei Hospital. After fourteen years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases, bringing together experts and scholars from across China to explore advances in the field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Robert Negrin, Director of the Division of Blood and Marrow Transplantation at Stanford University, for an in-depth interview. He shared his insights into milestone developments in regulatory T-cell (Treg) research, the clinical significance of the breakthrough achieved with Orca-T therapy, and future directions for expanding the Treg technology platform.